Overview

Micro Lab’s Arbitel contain Telmisartan that is considered as a group of drugs called
angiotensin II receptor antagonists.
Telmisartan protects the blood vessels from narrowing, which in turn helps to
lowers the blood pressure and improves blood flow within the vessel.
Telmisartan is primarily prescribed to treat high blood pressure (hypertension).
 In addition, sometimes It is given along with with other blood pressure
medications.
Telmisartan is also used to reduce the risk of stroke, heart attack, or death from
heart problems in people who are at least 55 years old with risk factors for serious
heart disorders.
Comparison of Sartans
General Instructions
Indications Listed in Dosage.
Dosage Adult: PO HTN Initial: 40 mg once daily, may be adjusted to 20-80 mg once daily. CV risk reduction 80 mg once daily.
Administration May be taken with or without food.
Concomitant use w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). Severe hepatic impairment. Pre
Contraindications
Volume- or salt-depleted patients including patients on prolonged diuretic therapy. Patients w/ renal
Special Precautions artery stenosis, aortic or mitral stenosis, obstructive biliary disease. Renal and mild to moderate hepatic
impairment. Lactation. Monitoring Parameters Monitor BP, electrolytes and serum creatinine levels.
Dizziness, fatigue, headache, sinusitis, upper resp tract infection, pharyngitis, UTI, back pain, myalgia,
Adverse Drug Reactions
diarrhoea, abdominal pain, dyspepsia, nausea.
Potentially Fatal: Intermittent claudication and skin ulcer.
May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma
levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing
Drug Interactions salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients
w/ diabetes and renal impairment (GFR <60 mL/min).
Food Interaction For caution against potential drug-food interactions
General Instructions
Indications Listed in Dosage.
A B C D X

Pregnancy Category (US FDA) Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women
may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
disease for which safer drugs cannot be used or are ineffective).
Mechanism of Action For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology
CIMS Class Angiotensin II Antagonists
ATC Classification C09CA07 - telmisartanBelongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.
Competitor’s Brand Available
Drug Contentc
Name Of the Company Code Brand Name Strength Hardnessa (Kg/cm2 ) DTb (Min) Amount (mg) Percentage (%)
GLN 40 40 04.87± 0.25 07.10-8.08 40.87 ± 0.94 102.17
Glenmark Pharmaceuticals Telma
GLN 80 80 06.8 ± 0.62 08.25-9.00 75.40 ± 2.87 94.25

ART 40 40 04.46± 0.45 03.08-3.45 39.01 ± 2.06 97.52

Aristo Pharmaceutical Pvt. Ltd Telvas
ART 80 80 11.12 ± 1.03 10.00-1.28 79.87 ± 3.21 99.83

LUP 40 40 03.75± 0.28 06 .01- 7.10 39.51 ± 3.03 98.77

Lupin LTD Telista
LUP 80 80 03.25 ± 1.19 06.05- 6.58 82.49 ± 0.95 103.11

INT 40 40 05± 0.81 08.06 -8.27 38.21 ± 1.69 95.52

Intas Pharmaceutical Sartel
INT 80 80 04.8 ± 0.25 09.30-10.21 81.90 ± 1.50 102.37

DRL 40 40 02± 0.40 05.30 -6.00 38.61 ± 2.10 96.52

Dr. Reddy’s Laboratory Telsartan
DRL 80 80 07.25 ± 0.86 07.35-8.00 82.12 ± 4.73 102.65

BI 40 40 08.62± 0.75 08.50 -9.00 39.51 ± 0.87 98.77

Boehringer Ingelheim Micardis
BI 80 80 07.87 ± 3.56 11.0-12.41 82.70 ± 1.24 103.37
a Data is expressed as mean ± S.D., (n = 4); b Data is expressed as mean ± S.D., (n = 6)
c Data is expressed as mean ± S.D., (n = 6);DT: Disintragration Time
SEGMENTATION

TARGETING

POSITIONING
geographic demographic

Ghana Millennial
Population

Urban Middle
people Aged

Male/Female

Middle to High
Income Group

Working Professionals
PSYCHOGRAPHIC
Attitude
and belief

Increasing health conscious consumers who prefer to have a safer and

healthier heart for smooth working lifestyle.
Currently, close to 11% of the global population is aged 60 years or over and
is estimated to reach nearly 22% by 2050. Since the risk of developing
pulmonary hypertension increases with age, a growing older population will
aid in the growth prospects of the hypertension drugs market in the coming
years
“We offer the most advanced Hypertension
Medicine for catering to the needs of working
professionals, aged between 25 to 70 years.”
“Choose Wisely, Live Safely ”
 Average Daily Consumption
Arbitel 20 Arbitel 40 Arbitel 80

3% 2% 2% 2% 1% 2% 2%

9% 8%
19%
20%

68%
76%
86%

Once a Day Twice a Day Thrice a Day Once a Day Twice a Day Twice a Week
Once a Day Twice a Day
Twice a Week Thrice a Week Alternate Day Thrice a Day
Twice a Week Thrice a Day
 Target Customer Market Penertarion
Cardiologist Out of 100% Cardiologist, 100% can prescribe Arbitel

Consultant Physician Out of 100% Consultant Physician, 20% can prescribe Arbitel

Diabetologist Out of 100% Diabetologist, 100% can prescribe Arbitel

Nephrologists Out of 100% Nephrologists, 25% can prescribe Arbitel. Post Renal Safety Data (On target
Trail)

Top End General Physician Out of 100% Top End General Physician, 13% can prescribe Arbitel
 After 3
Month

After
Launch
 After 9
Month

After 6
Month
After
12
Month
 Regular Visit for
Inform The Doctor Delivering Updated
Regarding Launching Scientific
of Arbitel Communication

Take Them Into Appreciate the Doctors

Confidence by with Good
Convincing Them Contribution towards
Regarding the Their Perticipation
Superiority of Arbitel
as Compared to Other
Brands
 Manufacturers

Mother
Godown

Our Activities Start

From This Point Stockist

Highest at This Point Retailers Sub Stockiest

Retailer Highest at This Point

 Ghana’s
Market Leader
Diversifying
Across Ghana

Increasing the
Number of
Prescribers
Small
Number of
Prescribers